omniture
logo
Search
Hinova Pharmaceuticals Inc
Media Room

Latest News

rss

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage bi...

2023-02-07 06:30 1827

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopha...

2023-02-06 21:10 1644

Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit

BOSTON, Oct. 29, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage ...

2022-10-29 05:30 8919

Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit

BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage ...

2022-10-28 20:30 2107

Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an orally bioavailable Chimeric Degrader targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Jan. 21, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage b...

2022-01-21 05:30 2080

Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage b...

2022-01-20 20:28 1451